Special Guidance on DEA's COVID-19 Response Concerning the Production of Controlled Substance Medications
Claire M. Brennan
Section Chief, Liaison Section, Diversion Control Division
U.S. Drug Enforcement Administration
Scott A. Brinks
Section Chief, Regulatory Drafting & Policy Support Section Diversion Control Division
Drug Enforcement Administration
Quarles & Brady LLP
Manatt, Phelps & Phillips, LLP
Complimentary Webinar Highlights:
During this global pandemic, the Diversion Control Division is working to assure that there is an adequate supply of controlled substances in the United States, while preventing the diversion of these controlled substances.
To help every link of the supply chain understand DEA’s tools and role during these unprecedented times, we invite you to join this informative webinar to learn firsthand about the guidance documents and exceptions to regulations that DEA has issued.
- Reviewing DEA’s COVID-19 responses
- Identifying challenges for suspicious order monitoring during the global pandemic
- Overcoming due diligence road blocks during social distancing
Complete the form below to download the recording of the webinar.
How We Will Use Your Data
If you decide that you no longer wish to receive information about our events and products, you can contact us any time at [email protected]. Each of our marketing communications (whether by email, phone, facsimile, post or SMS) will also include an appropriate and easy way for you to unsubscribe.
American Conference Institute
Two Park Avenue, 20th Floor
New York, NY 10016 USA
E: cust[email protected]